Earnings Troubles May Signal Larger Issues for Cannara Biotech (TSE:LOVE) Shareholders
The subdued market reaction suggests that Cannara Biotech Inc.'s (TSE:LOVE) recent earnings didn't contain any surprises. However, we believe that investors should be aware of some underlying factors which may be of concern.
One essential aspect of assessing earnings quality is to look at how much a company is diluting shareholders. Cannara Biotech expanded the number of shares on issue by 8.0% over the last year. Therefore, each share now receives a smaller portion of profit. To celebrate net income while ignoring dilution is like rejoicing because you have a single slice of a larger pizza, but ignoring the fact that the pizza is now cut into many more slices. You can see a chart of Cannara Biotech's EPS by clicking here.
How Is Dilution Impacting Cannara Biotech's Earnings Per Share (EPS)?
As you can see above, Cannara Biotech has been growing its net income over the last few years, with an annualized gain of 123% over three years. But EPS was only up 108% per year, in the exact same period. Net income was down 30% over the last twelve months. Unfortunately for shareholders, though, the earnings per share result was even worse, declining 33%. And so, you can see quite clearly that dilution is influencing shareholder earnings.
If Cannara Biotech's EPS can grow over time then that drastically improves the chances of the share price moving in the same direction. But on the other hand, we'd be far less excited to learn profit (but not EPS) was improving. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Cannara Biotech's Profit Performance
Cannara Biotech issued shares during the year, and that means its EPS performance lags its net income growth. Therefore, it seems possible to us that Cannara Biotech's true underlying earnings power is actually less than its statutory profit. But the good news is that its EPS growth over the last three years has been very impressive. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about Cannara Biotech as a business, it's important to be aware of any risks it's facing. Case in point: We've spotted 1 warning sign for Cannara Biotech you should be aware of.
This note has only looked at a single factor that sheds light on the nature of Cannara Biotech's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.